Novartis AG vs Teradata Corporation Common Stock — how do they compare? Novartis AG trades at $148.84 (market cap $279.90B), while Teradata Corporation Common Stock trades at $29.6 (market cap $2.78B). The key difference: Novartis AG is far larger — about 100.7× Teradata Corporation Common Stock's market cap, and Novartis AG pays a 3.23% dividend while Teradata Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Teradata Corporation Common Stock for 0 Days on average.
| NVS | TDC | |
|---|---|---|
Market Cap | $279.90B | $2.78B |
Volume | 1,647,300 | 1,442,176 |
Sector | Health | Technology |
52-Week High | $168.62 | $37.88 |
52-Week Low | $121.80 | $20.71 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $321.22B | $2.46B |
Dividend Yield | 3.23% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $142.41, down 0.99% with a bearish technical signal despite strong fundamentals including 74.74% gross margins and 30.55% ROE. Recent Q2 2026 EPS beat expectations at $2.41 versus $2.17, though Q1 missed. The company announced a $7.8B licensing deal with China's Abogen for mRNA therapy, while facing clinical setbacks in ALS drug development and investor scrutiny over M&A strategy.
The stock presents a mixed outlook with solid profitability and growth potential from new deals, but technical weakness and recent trial failures pose near-term risks. Analyst consensus at $146 target suggests modest upside, though bearish sentiment from 68% hold ratings indicates caution amid pipeline uncertainties and competitive pressures in pharma.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Teradata Corporation develops a hybrid cloud analytics and data platform, including its Teradata Vantage and VantageCloud products, that helps enterprises manage and analyze data across cloud, on-premises, and hybrid environments. It serves industries including retail, financial services, healthcare, and manufacturing.
Read more on TDC →